REDUCEDT+7
Lippman Evan
Teva Pharmaceutical Industries · NASDAQ
−18,600 sh · $680.3K
Filed 19 Aug 2026SEC Form 4view source
BlackRock
13F filer
$698.6M
42,987,782 sh
Viking Global Investors
13F filer
$51.1M
2,532,119 sh
Bridgewater Associates
13F filer
$44.9M
1,326,678 sh
Duquesne Family Office
13F filer
$21.2M
624,999 sh
Two Sigma Investments
13F filer
$11.0M
366,791 sh
Greenlight Capital
13F filer
$2.8M
268,470 sh
ARK Investment Management
13F filer
$2.3M
68,653 sh
Lippman Evan
Teva Pharmaceutical Industries · NASDAQ
−18,600 sh · $680.3K
ARK Investment Management
Teva Pharmaceutical Industries · NASDAQ
68,653 sh · $2.3M
Bridgewater Associates
Teva Pharmaceutical Industries · NASDAQ
1,326,678 sh · $44.9M
Duquesne Family Office
Teva Pharmaceutical Industries · NASDAQ
624,999 sh · $21.2M
Two Sigma Investments
Teva Pharmaceutical Industries · NASDAQ
366,791 sh · $11.0M
Duquesne Family Office
Teva Pharmaceutical Industries · NASDAQ
2,377,285 sh · $71.6M
Bridgewater Associates
Teva Pharmaceutical Industries · NASDAQ
1,128,406 sh · $34.0M
ARK Investment Management
Teva Pharmaceutical Industries · NASDAQ
68,279 sh · $2.1M
Duquesne Family Office
Teva Pharmaceutical Industries · NASDAQ
5,874,870 sh · $183.4M
ARK Investment Management
Teva Pharmaceutical Industries · NASDAQ
105,131 sh · $3.3M